Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre.
Alexander ScheiterFrederik HierlFlorian LükeFelix KeilDaniel HeudoblerSabine EinhellMargit Klier-RichterNikola P KonstandinFlorian WeberAndrea ScheiterArne KandulskiSophie SchlosserLidia-Sabina CosmaHauke TewsAndreas R R WeissMatthias GrubeElisabeth BumesPeter HauMartin ProescholdtFelix StegerAnja TroegerSebastian HaferkampLucas E ReibenspiesMarco J SchnabelChristian SchulzKonstantin DrexlerMaria E HatzipanagiotouStephan SeitzMonika Klinkhammer-SchalkePhilipp UnberathDiego F CalvisiTobias PukropWolfgang DietmaierMatthias EvertKirsten UtpatelPublished in: British journal of cancer (2022)
The CCCO MTB yielded a considerable recommendation rate, particularly in cholangiocarcinoma patients. The discrepancy between the low-recommendation rates in colorectal and pancreatic cancer suggests the necessity of a weighted prioritisation of entities. High-tier recommendations should be implemented predominantly.
Keyphrases